Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/8/13  and contains information from public web pages.

Dr. Thomas J. Walsh

Wrong Dr. Thomas J. Walsh?

Head of Immune-Compromised Host D...

Phone: (800) ***-****  HQ Phone
National Cancer Institute
6116 Executive Blvd. Room 3036A
Bethesda , Maryland 20892
United States

Company Description: The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in...   more

Employment History

Board Memberships and Affiliations


  • MD
    Univ. of Washington
  • M.D.
25 Total References
Web References
Fungalite Phase 1 (Pot Of 120 Capsules), 8 July 2013 [cached]
Ref: . Thomas J. Walsh, M.D., head of immune-compromised host division of the National Cancer Institute of Bethesda, Maryland.
IDSA: Guidelines Advocate Vfend (voriconazole) for Invasive Aspergillus - CME Teaching Brief - MedPage Today [cached]
New clinical trial evidence indicates that Vfend, an antifungal newcomer, is more effective than amphotericin B in treating invasive aspergillosis, said Thomas Walsh, M.D., of the National Cancer Institute's Pediatric Oncology Branch.The fungal infection can be deadly for immunocompromised patients, such as those undergoing chemotherapy or stem cell transplantation.
The guidelines, proposed by an IDSA committee, must still be finalized by the full organization."Amphotericin B has been considered the gold standard for treatment of invasive aspergillosis," said Dr. Walsh.But on the basis of the results of a randomized, controlled trial, "which demonstrated superiority of voriconazole, the committee agreed that voriconazole be considered the initial primary therapy for invasive aspergillus."
In that trial, about 53% of patients treated with Pfizer's Vfend achieved a complete or partial response from invasive aspergillosis compared with about 32% of patients given amphotericin B.
Under the proposed guidelines, Dr. Walsh said, patients diagnosed with invasive aspergillosis would first be assessed for treatment with parenteral or oral therapy based on host factors, time factors, and bioavailability.
"If aspergillosis were not so difficult a disease to study we would have answers to all those questions," Dr. Walsh said.
He said clinical trials are being organized to test whether combination therapy improves outcomes in cases where Vfend treatment does not cure.He said there is no evidence to say whether combination salvage therapy would be more successful than follow-up amphotericin or increasing the dosage of Vfend.
Over the weekend, the Los Angeles ..., 2 July 2007 [cached]
Over the weekend, the Los Angeles Times reported how one researcher at NCI, Thomas Walsh, between 1997 and 2003 worked on a succession of clinical trials for new antifungal drugs for treating serious lung infections associated with cancer, and, at the same time, took consulting fees from the companies that manufactured those drugs, including Pfizer and Merck.
The investigation also went on to question the protocols of the second of the two trials, which compared the newer Merck drug to the older one made by Fujisawa and marketed by Pfizer, which Walsh had also worked on.
Whether Dr. Walsh violated one of NIH's rules for disclosing conflicts of interest is hardly the most important question here.What's really important is giving health care professionals the best information possible for conducting the most effective and most cost effective medicine.
When NIH was debating its new rules in 2004 in the wake of Willman's previous articles documenting undisclosed conflicts of interest at the agency, I was one of the few people to stand up and call for a total ban on such arrangements.It's not that the government shouldn't collaborate with industry to bring exciting new therapies to market, I said.Rather, the government has a crucial role to play as independent designer of those trials and arbiter of the evidence.It must ensure that the information generated by government involvement in clinical trials testing the drug industry's latest medicines furthers public health.
It would appear that the government-funded studies that Walsh conducted failed these basic tests.
Thomas J. Walsh, M.D. ..., 22 July 2004 [cached]
Thomas J. Walsh, M.D.
Thomas J. Walsh, M.D.
Thomas J. Walsh, MD ... [cached]
Thomas J. Walsh, MD National Cancer Institute
Thomas J. Walsh, MD
Moderator: Thomas J. Walsh, MD
Thomas J. Walsh, MD
Other People with the name "Walsh":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.